(:THRX)

Feb 14, 2024 07:30 am ET
Theseus Pharmaceuticals Announces Closing of Tender Offer
-- Theseus Stockholders to Receive $4.05 Per Share in Cash Plus Contingent Value Right --
Feb 05, 2024 07:32 pm ET
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - AMAM, TGAN, CSTR, THRX
NEW YORK, Feb. 5, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are now investigating:
Jan 30, 2024 08:00 am ET
Concentra Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Theseus Pharmaceuticals
As previously announced on December 22, 2023, Concentra Biosciences, LLC (“Parent”) and its wholly owned subsidiary, Concentra Merger Sub II, Inc. (“Purchaser”), entered into a merger agreement (the “Merger Agreement”) with Theseus Pharmaceuticals, Inc. (Nasdaq: THRX) (“Theseus”) whereby Purchaser will acquire Theseus for a price per share of Theseus common stock ("Theseus common stock") between $3.90 and $4.05 in cash, consisting of (i) a base cash price of $3.90 per share (the "Base Price") and (ii) an additional cash amount of up to $0.15 per share (the “Additional Price Per Share” and toge
Jan 25, 2024 08:09 am ET
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates CSTR, PGTI, THRX
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: CapStar Financial Holdings, Inc....
Jan 24, 2024 05:16 pm ET
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – AMAM, CSTR, RYZB, THRX
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and...
Jan 23, 2024 01:45 pm ET
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates PGTI, X, THRX, AYX
NEW YORK, Jan. 23, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jan 22, 2024 02:41 pm ET
THESEUS PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Theseus Pharmaceuticals, Inc.
NEW ORLEANS, Jan. 22, 2024 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Theseus Pharmaceuticals, Inc. (NasdaqGS: THRX) to Concentra Biosciences, LLC. Under the terms of the proposed transaction, shareholders of Theseus will receive between $3.90 and $4.05 in cash for each share of Theseus that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Jan 19, 2024 08:00 pm ET
SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – RYZB, THRX, AMAM, CSTR
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and...
Jan 17, 2024 12:00 am ET
SHAREHOLDER RIGHTS INVESTIGATION: Halper Sadeh LLC Investigates PGTI, KRTX, THRX, GRCL
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: PGT Innovations, Inc. (NYSE: PGTI)’s...
Jan 13, 2024 08:53 am ET
SHAREHOLDER RIGHTS INVESTIGATION: Halper Sadeh LLC Investigates CVLY, PGTI, KRTX, THRX
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Codorus Valley Bancorp, Inc. (NASDAQ:...
Jan 12, 2024 07:35 pm ET
SHAREHOLDER ALERT: Juan Monteverde Encourages the Shareholders of CVLY, THRX, SOLO, SWN to Take Action
NEW YORK, Jan. 12, 2024 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating:
Jan 10, 2024 11:00 pm ET
SHAREHOLDER RIGHTS INVESTIGATION: Halper Sadeh LLC Investigates DSKE, THRX, CONN
NEW YORK, Jan. 11, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jan 01, 2024 09:21 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PGTI, AYX, KRTX, THRX
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: PGT Innovations, Inc. (NYSE: PGTI)’s...
Dec 31, 2023 05:56 pm ET
THESEUS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Theseus Pharmaceuticals, Inc.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Theseus Pharmaceuticals, Inc. (NasdaqGS: THRX) to Concentra Biosciences, LLC. Under the terms of the proposed transaction, shareholders of Theseus will receive between $3.90 and $4.05 in cash for each share of Theseus that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Dec 27, 2023 04:24 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DSKE, KRTX, THRX, CONN
NEW YORK, Dec. 27, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Dec 22, 2023 11:26 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DSKE, KRTX, THRX
NEW YORK, Dec. 22, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Dec 22, 2023 08:51 am ET
Shareholder Alert: Ademi LLP investigates whether Theseus Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Concentra
MILWAUKEE, Dec. 22, 2023 /PRNewswire/ -- Ademi LLP is investigating Theseus (NASDAQ: THRX) for possible breaches of fiduciary duty and other violations of law in its transaction with Concentra.
Dec 22, 2023 08:31 am ET
Thinking about buying stock in Porch Group, Hookipa Pharma, Wheels Up Experience, Theseus Pharmaceuticals, or Allovir?
NEW YORK, Dec. 22, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PRCH, HOOK, UP, THRX, and ALVR.
Dec 22, 2023 08:24 am ET
THRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Theseus Pharmaceuticals, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) to Concentra Biosciences, LLC for between $3.90 and $4.05 in cash is fair to Theseus shareholders.
Dec 22, 2023 05:30 am ET
Theseus Pharmaceuticals Enters into Agreement to Be Acquired by Concentra Biosciences for between $3.90 and $4.05 in Cash per Share Plus a Contingent Value Right
CAMBRIDGE, Mass., Dec. 22, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus" or the "Company"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced it has entered into a definitive merger agreement (the "Merger Agreement") whereby Concentra Biosciences, LLC ("Concentra") will acquire Theseus for a price per share of Theseus common stock ("Theseus common stock") of between $3.90 and $4.05 in cash, consisting of (i)
Nov 27, 2023 08:31 am ET
Thinking about buying stock in Perfect Corp, UP Fintech, Theseus Pharmaceuticals, Reliance Sekuritas Indonesia, or Ardelyx?
NEW YORK, Nov. 27, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PERF, TIGR, THRX, RELI, and ARDX.
Nov 27, 2023 05:30 am ET
Theseus Pharmaceuticals Confirms Receipt of Unsolicited Expression of Interest from Foresite Capital, LLC and OrbiMed Advisors LLC and Unsolicited Proposal from Concentra Biosciences LLC
CAMBRIDGE, Mass., Nov. 27, 2023 /PRNewswire/ -- On November 22, 2023, the board of directors (the Board) of Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company) received an unsolicited joint letter from funds and persons affiliated with Foresite Capital, LLC (collectively, Foresite) and funds and persons affiliated with OrbiMed Advisors LLC (collectively, OrbiMed), in which Foresite and OrbiMed indicated their intent to explore and evaluate a potential acquisition of all of the outstanding shares of common stock of the Company not already owned by Foresite or OrbiMed in a go
Nov 15, 2023 08:31 am ET
Thinking about buying stock in Tesla Inc, Chevron, Theseus Pharmaceuticals, Cybin Inc, or NXU Inc.?
NEW YORK, Nov. 15, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TSLA, CVX, THRX, CYBN, and NXU.
Nov 14, 2023 08:31 am ET
Thinking about buying stock in Theseus Pharmaceuticals, Vuzix, Jaguar Global Growth, Fisker, or Cardio Diagnostics Holdings?
NEW YORK, Nov. 14, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for THRX, VUZI, JGGC, FSR, and CDIO.
Nov 13, 2023 03:05 pm ET
Theseus Pharmaceuticals Announces Process to Explore Strategic Alternatives
CAMBRIDGE, Mass., Nov. 13, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced that it is conducting a process exploring strategic alternatives to maximize shareholder value.
Nov 07, 2023 03:05 pm ET
Theseus Pharmaceuticals to Participate in the Stifel 2023 Healthcare Conference
CAMBRIDGE, Mass., Nov. 7, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced that the company will participate in a fireside chat at the Stifel 2023 Healthcare Conference on Tuesday, November 14 at 9:45 a.m. ET.
Jul 17, 2023 09:31 am ET
Thinking about buying stock in AMC Entertainment, Archer Aviation, Theseus Pharmaceuticals, Quantumscape, or Acumen Pharmaceuticals?
NEW YORK, July 17, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMC, ACHR, THRX, QS, and ABOS.
Jul 14, 2023 09:31 am ET
Thinking about buying stock in Knightscope, Mullen Automotive, Nikola, Ideanomics, or Theseus Pharmaceuticals?
NEW YORK, July 14, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for KSCP, MULN, NKLA, IDEX, and THRX.
Jul 13, 2023 04:05 pm ET
Theseus Pharmaceuticals to Discontinue Enrollment in Phase 1/2 Study and Terminate Development of THE-630 in Patients with GIST
-- Decision follows two dose-limiting toxicities related to hand-foot skin reaction observed in Cohort 7 (27 mg) --
May 31, 2023 07:00 am ET
Theseus Pharmaceuticals to Participate in the Jefferies Healthcare Conference
CAMBRIDGE, Mass., May 31, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that the company will participate in a live Fireside Chat at the Jefferies Healthcare Conference on June 8th at 10:30am ET.
May 25, 2023 05:01 pm ET
Theseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1/2 Trial of THE-630 in Patients with Advanced GIST
-- THE-630 demonstrates encouraging safety profile through Cohort 6 (18 mg), supportive of continued dose escalation --
May 11, 2023 07:00 am ET
Theseus Pharmaceuticals Announces Business Highlights and Reports First Quarter 2023 Financial Results
-- THE-630 initial dose escalation data to be presented at investor event on May 25, 2023, with additional dose escalation data expected in Q4 2023 --
Apr 26, 2023 10:05 am ET
Apr 11, 2023 07:00 am ET
Theseus Pharmaceuticals to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., April 11, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that the company will participate virtually in the following upcoming investor conferences:
Mar 28, 2023 07:00 am ET
Theseus Pharmaceuticals to Participate in the Cantor Future of Oncology Virtual Symposium
CAMBRIDGE, Mass., March 28, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that the company will participate in the Cantor Future of Oncology Virtual Symposium, taking place April 3-5, 2023.
Mar 09, 2023 06:00 am ET
Theseus Pharmaceuticals Announces Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results
THE-630 phase 1 preliminary dose-escalation data anticipated in Q2 2023; additional data including dose levels projected preclinically to provide pan-variant KIT coverage planned for Q4 2023
Feb 07, 2023 06:00 am ET
Theseus Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
CAMBRIDGE, Mass., Feb. 7, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that the Company will participate virtually in the SVB Securities Global Biopharma Conference, taking place February 14-16, 2023.
Jan 05, 2023 06:00 am ET
Theseus Pharmaceuticals Highlights Key Anticipated 2023 Milestones and Announces BCR-ABL as Target for Third Development Program
Progressing Phase 1/2 clinical trial of THE-630 in advanced GIST; preliminary dose-escalation data anticipated in Q2 2023 with additional data expected in Q4 2023
Nov 03, 2022 07:00 am ET
Theseus Pharmaceuticals Announces Business and Pipeline Highlights and Reports Third Quarter 2022 Financial Results
All sites open and actively enrolling in Phase 1 portion of Phase 1/2 clinical trial of THE-630 in advanced GIST; preliminary dose escalation data expected in Q2 2023
Oct 26, 2022 07:00 am ET
Theseus Pharmaceuticals Presents Preclinical Data Characterizing THE-349, its Fourth-Generation EGFR Inhibitor in Development for NSCLC, at the 34th EORTC-NCI-AACR Symposium
Potent single-molecule inhibition of all major classes of EGFR activating and resistance mutations, including C797X and T790M, with a high degree of kinome and wild-type EGFR selectivity
Oct 19, 2022 07:00 am ET
Theseus Pharmaceuticals Appoints Steven Stein, M.D. to Board of Directors
CAMBRIDGE, Mass., Oct. 19, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced the appointment of Steven Stein, M.D. to its Board of Directors. 
Oct 03, 2022 07:00 am ET
Theseus Pharmaceuticals Nominates THE-349, a Fourth-Generation EGFR Inhibitor Development Candidate in Non-Small Cell Lung Cancer
 THE-349 is a fourth-generation, potent and selective, small molecule designed to inhibit all major classes of EGFR activating and resistance mutations
Sep 06, 2022 08:30 am ET
Theseus Pharmaceuticals to Participate at Upcoming September Investor Conferences
CAMBRIDGE, Mass., Sept. 6, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that the company will participate in-person at the following upcoming investor conferences:
Aug 11, 2022 07:00 am ET
Theseus Pharmaceuticals Announces Business and Pipeline Highlights and Reports Second Quarter 2022 Financial Results
THE-630 Phase 1/2 clinical trial enrolling patients; initial data expected in Q2 2023
Aug 03, 2022 08:30 am ET
Theseus Pharmaceuticals to Participate Virtually in Wedbush PacGrow Healthcare Conference
CAMBRIDGE, Mass., Aug. 3, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that it will participate virtually in the 2022 Wedbush PacGrow Healthcare Conference, taking place August 9-10, 2022.
May 19, 2022 08:30 am ET
Theseus Pharmaceuticals to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., May 19, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that the company will participate virtually in the H.C. Wainwright Global Investment Conference taking place May 23-26, 2022 and in-person in the Jefferies Healthcare Conference taking place June 8-10, 2022.
May 18, 2022 08:30 am ET
Theseus Pharmaceuticals Appoints Don Hayden to Board of Directors
CAMBRIDGE, Mass., May 18, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced the appointment of Don Hayden to its Board of Directors.
May 12, 2022 07:00 am ET
Theseus Pharmaceuticals Announces Business Highlights and Reports First Quarter 2022 Financial Results
THE-630 Phase 1/2 clinical trial actively enrolling patients with advanced gastrointestinal stromal tumors (GIST); initial data expected in 1H 2023
Apr 08, 2022 01:00 pm ET
Theseus Pharmaceuticals Announces Preclinical Data Characterizing Next-Generation Epidermal Growth Factor Receptor (EGFR) Inhibitors at the 2022 American Association for Cancer Research (AACR) Annual
Poster presentation details lead compounds demonstrating activity against EGFR variants that are resistant to all approved EGFR inhibitors
Apr 05, 2022 08:30 am ET
Theseus Pharmaceuticals to Participate Virtually in Needham Healthcare Conference
CAMBRIDGE, Mass., April 5, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that it will participate in the 21st Annual Needham Virtual Healthcare Conference, taking place April 11-14, 2022.
Mar 10, 2022 06:00 am ET
Theseus Pharmaceuticals Announces Business Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results
CAMBRIDGE, Mass., March 10, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced business highlights and reported financial results for the fourth quarter and full year ended December 31, 2021.
Mar 08, 2022 04:01 pm ET
Theseus Pharmaceuticals to Present Preclinical Data Characterizing Next-Generation Epidermal Growth Factor Receptor (EGFR) Inhibitors at the 2022 American Association for Cancer Research (AACR) Annual
CAMBRIDGE, Mass., March 8, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that the Company will present a poster highlighting the characterization of potent and selective next-generation EGFR inhibitors at the American Association for Cancer Research (AACR) 2022 Annual Meeting, being held April 8-13, 2022 in New Orleans, Louisiana.
Feb 09, 2022 06:30 am ET
Theseus Pharmaceuticals to Participate Virtually in SVB Leerink Global Healthcare Conference
CAMBRIDGE, Mass., Feb. 9, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that Tim Clackson, Ph.D., President and Chief Executive Officer of Theseus, will participate in a virtual fireside chat for the 11th Annual SVB Leerink Global Healthcare Conference, taking place February 14-18, 2022.
Feb 02, 2022 06:30 am ET
Theseus Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for THE-630 for the Treatment of Advanced Gastrointestinal Stromal Tumors (GIST)
CAMBRIDGE, Mass., Feb. 2, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (Theseus) (NASDAQ: THRX), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to the company's lead candidate THE-630, a small-molecule oral pan-variant KIT inhibitor, for the treatment of patients with advanced gastrointestinal stromal tumors (GIST).
Dec 17, 2021 07:00 am ET
Omega Funds Closes Oversubscribed $650 Million Fund VII to Invest in Transformative Life Science Companies
BOSTON, Dec. 17, 2021 /PRNewswire/ -- Omega Funds, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced it has closed its seventh and largest fund with $650 million in limited partner capital commitments. The new fund, Omega Fund VII, L.P. ("Fund VII"), was oversubscribed, exceeding the firm's targeted raise of $500 million, and included strong support from both new and existing limited partners. With Fund VII, the firm will continue to execute on its strategy of creating and investing in life sciences companies in the
Nov 15, 2021 06:00 am ET
Theseus Pharmaceuticals Announces Business and Program Highlights and Reports Third Quarter 2021 Financial Results
CAMBRIDGE, Mass., Nov. 15, 2021 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX), a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced business and program highlights and reported financial results for the third quarter ended September 30, 2021.
Nov 10, 2021 06:00 am ET
Theseus Pharmaceuticals to Participate Virtually in Jefferies London Healthcare Conference
CAMBRIDGE, Mass., Nov. 10, 2021 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that Tim Clackson, Ph.D., President and Chief Executive Officer of Theseus, will participate in a virtual fireside chat for the 12th Annual Jefferies London Healthcare Conference, taking place November 16-19, 2021.
Oct 06, 2021 10:20 pm ET
Theseus Pharmaceuticals Announces Pricing of Initial Public Offering
CAMBRIDGE, Mass., Oct. 6, 2021 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. ("Theseus"), a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced the pricing of its initial public offering of 10,000,200 shares of its common stock at a price to the public of $16.00 per share. All of the shares are being offered by Theseus. The gross proceeds to Theseus from the offering, before deducting underwriting discounts, commissions and other offering expenses payable by

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.